MLYS - Mineralys Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.00
DETAILS
HIGH:
$56.00
LOW:
$30.00
MEDIAN:
$43.00
CONSENSUS:
$43.00
UPSIDE:
51.52%
About Mineralys Therapeutics, Inc. (https://mineralystx.com)
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jon Congleton | President, Chief Executive Officer & Director | 1963 | $1,109,101 USD |
| David Rodman | Chief Medical Officer | 1955 | $881,798 USD |
| Adam Scott Levy | Chief Financial Officer & Secretary | 1978 | $880,190 USD |
| Brian Taylor Slingsby | Founder & Executive Director | 1977 | $78,000 USD |
| Danielle Mahoney | Senior Vice President of Quality Assurance | – | – |
| Eric J. Warren | Chief Commercial Officer | 1972 | – |
| Jeffrey A. Munsie | Chief Legal Officer | 1977 | – |
| Jessica Ibbitson | Executive Vice President of Operations | – | – |
| Robert McKean | Senior Vice President of CMC | – | – |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | – | – |